|
Jul 1
|
NervGen Announces Clinical Leadership Transition as NVG-291 Continues to Advance Toward Late-Stage Development and Regulatory Milestones
|
|
May 16
|
NervGen Pharma Grants Stock Options
|
|
May 15
|
NervGen Pharma Reports Q1 2025 Financial Results and Provides Operational Updates
|
|
May 2
|
TSX Penny Stock Insights For May 2025
|
|
Apr 9
|
NervGen Provides Quarterly "At-The-Market" Equity Program Update
|
|
Jan 2
|
NervGen Completes Enrollment in Chronic Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury
|